Testicular Ultrasonography and 18G Biopty Biopsy for Clinically Undetected Cancer or Carcinoma in situ in Patients with Germ Cell Tumours
- 1 February 1993
- journal article
- Published by Wiley in British Journal of Urology
- Vol. 71 (2), 214-216
- https://doi.org/10.1111/j.1464-410x.1993.tb15921.x
Abstract
The 18G Biopty biopsy has been evaluated as a tool to detect carcinoma in situ in the remaining testes of patients with extragonadal germ cell tumours or unilateral germ cell tumours. In all, 68 biopsies were performed in 57 selected patients. Five carcinomas in situ and 1 infiltrative seminoma were detected. The biopsies were performed under local anaesthesia. Pain and/or haematomas occurred after 9 of the 68 biopsies but none of the haematomas required invasive measures. This method of performing biopsies from clinically tumour-free testes seems promising but longer follow-up is required to evaluate the sensitivity of the method compared with open surgical biopsy.Keywords
This publication has 9 references indexed in Scilit:
- Serum Follicle Stimulating Hormone–Predictor of Cancer in the Remaining Testis in Patients with Unilateral Testicular CancerBritish Journal of Urology, 1990
- Use of Biopty Gun for Transcutaneous Testicular BiopsiesJournal of Urology, 1989
- Carcinoma in Situ of the TestisJournal of Urology, 1989
- CARCINOMA-IN-SITU TESTIS IN PATIENTS WITH ASSUMED EXTRAGONADAL GERM-CELL TUMOURSThe Lancet, 1987
- Testicular biopsy as an outpatient procedure in screening for carcinoma-in-situ: complications and the patient's acceptanceInternational Journal of Andrology, 1987
- Management of carcinoma‐in‐situ of the testisInternational Journal of Andrology, 1987
- Pathologic findings at orchiectomy following chemotherapy for disseminated testicular cancer.Journal of Clinical Oncology, 1984
- Screening for carcinoma in situ of the contralateral testis in patients with germinal testicular cancer.BMJ, 1982